Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns
BioNTech's breast cancer drug meets its Phase 3 endpoint but serious lung toxicity raises concerns. Explore the results and approval outlook.
Pharma & Biotech
Pharma & Biotech
Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.